Pulmonary Hypertension Treatment in Malaysia
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is Pulmonary Hypertension?
Pulmonary Hypertension (PH) is a group of conditions in which blood pressure in the pulmonary arteries is abnormally high. This increases the workload on the right side of the heart and, if persistent, can lead to right-heart enlargement and failure.
PH is classified into five groups based on its underlying cause:
- Group 1 - Pulmonary Arterial Hypertension (PAH): Affects the pulmonary arteries and may be idiopathic, inherited, drug-related, or associated with conditions such as connective tissue disease or congenital heart disease.
- Group 2 - PH Due to Left Heart Disease: Caused by conditions such as heart failure or left-sided valve disease.
- Group 3 - PH Due to Lung Disease or Hypoxia: Associated with conditions such as COPD, interstitial lung disease, or chronic low oxygen levels.
- Group 4 - PH Due to Pulmonary Artery Obstructions: Includes chronic thromboembolic pulmonary hypertension (CTEPH).
- Group 5 - PH With Unclear or Multifactorial Causes: Includes conditions with multiple or less clearly understood mechanisms.
What is the Importance of Timely Treatment?
Timely diagnosis allows clinicians to identify the underlying type of PH, assess disease severity and right-heart function, and select appropriate treatment. Severe or rapidly worsening breathlessness, chest pain, fainting, blue or grey lips, or sudden breathlessness with chest pain should receive urgent medical assessment.
What are the Common Symptoms of Pulmonary Hypertension?
- Shortness of Breath: Breathlessness may start during exercise and become more frequent as the condition progresses.
- Fatigue and Weakness: Reduced exercise capacity and impaired blood flow can cause persistent tiredness or weakness.
- Chest Discomfort or Pain: Some patients experience chest pressure or pain, particularly during exertion.
- Dizziness or Fainting: Reduced ability of the cardiovascular system to increase blood flow during activity may cause lightheadedness or syncope.
- Swelling of the Legs and Feet: Right-sided heart strain can contribute to fluid accumulation in the lower limbs.
- Abdominal or Facial Swelling: Fluid retention may sometimes cause abdominal swelling or other signs of congestion.
- Rapid or Irregular Heartbeat: Some patients may have palpitations.
- Cough or Wheezing: Coughing or wheezing may occur, particularly when PH is associated with underlying lung disease.
- Coughing Up Blood: Hemoptysis can occur in some patients and requires medical evaluation.
Causes and Risk Factors of Pulmonary Hypertension
Causes
- Pulmonary Arterial Disease: Abnormal narrowing or remodelling of the pulmonary arteries can cause Group 1 PAH.
- Left-Sided Heart Disease: Heart failure, cardiomyopathy, and left-sided valvular disease can increase pressure in the pulmonary circulation.
- Chronic Lung Disease: COPD, interstitial lung disease, emphysema, and other chronic respiratory disorders may contribute to PH.
- Chronic Hypoxia: Long-term low oxygen levels can contribute to pulmonary vascular changes.
- Chronic Blood Clots: Persistent obstruction of pulmonary arteries can cause CTEPH.
- Congenital Heart Disease: Certain congenital heart defects can increase pulmonary blood flow or pressure.
- Connective Tissue Diseases: Conditions such as systemic sclerosis and other connective tissue disorders may be associated with PAH.
- Liver and Portal Circulation Disorders: Portal hypertension and certain liver diseases can be associated with PAH.
- HIV Infection: HIV infection is associated with an increased risk of pulmonary arterial hypertension.
- Blood and Metabolic Disorders: Certain haematological, metabolic, or systemic conditions can contribute to PH.
- Genetic Factors: Some forms of PAH have an inherited component.
Risk Factors
- Family history of pulmonary hypertension
- Certain genetic disorders
- Congenital heart disease
- Connective tissue diseases
- Chronic lung disease
- Sleep-disordered breathing
- Previous or recurrent pulmonary blood clots
- Liver disease or portal hypertension
- HIV infection
- Certain medications or toxins
- Smoking
- Increasing age
- Conditions associated with chronic low oxygen levels
Latest Research and Technologies in the Treatment of Pulmonary Hypertension in Malaysia
- Advances in pulmonary hypertension care include improved echocardiography, right-heart catheterisation, cardiac MRI, and ventilation/perfusion (V/Q) scanning to support diagnosis, risk assessment, and treatment planning. Selected patients with pulmonary arterial hypertension may benefit from combination therapies targeting different pathways involved in pulmonary blood-vessel narrowing. For chronic thromboembolic pulmonary hypertension (CTEPH), treatment may combine pulmonary endarterectomy, balloon pulmonary angioplasty, and targeted medical therapy, depending on operability and disease characteristics. Access to these specialised investigations and procedures varies between hospitals and referral centres in Malaysia.
Treatment options for Pulmonary Hypertension
PDA Closure : A catheter-based or surgical procedure may be considered when a persistent ductus arteriosus is causing clinically significant problems, and closure is appropriate. Specialist haemodynamic assessment is essential because closing a shunt can be harmful in some patients with advanced pulmonary vascular disease.
Cost Start From 5000Explore Options
Guideline-Directed Medical Therapy (GDMT): The prognostic "four-pillar" medication regimen consisting of an ARNI/ACE inhibitor, an evidence-based beta-blocker, an SGLT2 inhibitor, and a mineralocorticoid receptor antagonist to stop ventricular remodelling.
Loop Diuretic Therapy: Diuretics may be prescribed to reduce fluid retention, leg swelling, and abdominal congestion in patients with right-sided heart failure. Treatment requires monitoring of kidney function, blood pressure, and electrolytes.
Mechanical Circulatory Support (LVAD Implantation) : The surgical placement of an implantable mechanical heart pump to assist or completely take over the workload of a failing left ventricle in advanced disease stages.
Orthotopic Heart Transplantation : The definitive, terminal surgical option where the patient's severely damaged, failing heart is completely removed and replaced with a healthy donor heart.
- Clinical assessment:
- Medical History: Assessment includes breathlessness, exercise tolerance, chest pain, dizziness, fainting, swelling, previous blood clots, heart and lung diseases, connective tissue disorders, medications, family history, and relevant exposures.
- Physical Examination: Clinicians may assess oxygen saturation, heart sounds, lung sounds, neck veins, peripheral swelling, liver enlargement, blood pressure, heart rate, and other signs of right-heart strain.
- Electrocardiogram (ECG): May identify right-heart strain, rhythm abnormalities, or other cardiac findings.
- Blood Tests: Tests may assess blood counts, kidney and liver function, thyroid function, iron status, biomarkers of cardiac stress, and possible associated diseases.
- BNP or NT-proBNP: These biomarkers may help assess cardiac strain and are also useful for risk assessment and monitoring in appropriate patients.
- Pulmonary Function Tests: Spirometry, lung volumes, and diffusion capacity can help identify underlying lung disease.
- Oxygen Assessment: Pulse oximetry and, when indicated, arterial blood gas testing can evaluate oxygenation.
- Imaging Tests:
- Transthoracic Echocardiography: A key non-invasive test for assessing right-heart structure and function and estimating the probability of pulmonary hypertension.
- Transesophageal Echocardiography: May provide additional cardiac and structural information in selected patients.
- Chest X-Ray: Can help identify changes involving the heart, lungs, or pulmonary arteries and may support evaluation of other causes of symptoms.
- Ventilation/Perfusion (V/Q) Scan: Particularly useful for evaluating chronic thromboembolic disease.
- CT Pulmonary Angiography: Provides detailed images of pulmonary arteries and surrounding structures and may help identify thromboembolic or other causes.
- High-Resolution CT: May be used to evaluate interstitial lung disease, emphysema, or other lung abnormalities.
- Cardiac MRI: Provides detailed assessment of right- and left-heart structure and function and may be useful for selected patients.
- Right-Heart Catheterisation: Directly measures pulmonary pressures and other haemodynamic parameters and is an important test to confirm and characterise PH when clinically indicated.
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive tele-rehabilitation services designed to support Pulmonary Hypertension patients in Malaysia. These services include:
- Supervised Exercise Training: Selected stable patients may benefit from supervised, individually prescribed exercise programmes.
- Pulmonary Rehabilitation: Rehabilitation can help improve exercise capacity, physical function, and confidence in appropriate patients.
- Breathing and Energy-Conservation Techniques: Patients may learn techniques to manage breathlessness and conserve energy during daily activities.
- Gradual Activity Progression: Increase exercise intensity according to symptoms, functional capacity, oxygen levels, and specialist guidance.
- Oxygen Management: Patients who need supplemental oxygen should use it as prescribed, especially during activity or sleep when indicated.
- Long-Term Follow-Up: Regular assessment of symptoms, exercise capacity, right-heart function, oxygenation, and treatment response is important.
- Pulmonary Hypertension Medication depends on its group, severity, and underlying cause. Group 1 PAH: antagonists, inhibitors, stimulators, analogues, receptor agonists, and calcium channel blockers in selected patients. Group 2: heart-failure medicines, diuretics, and valve-directed treatments. Group 3: oxygen therapy, inhaled therapies, and medicines for the underlying lung disease. Group 4: anticoagulants, pulmonary vasodilators, and selected targeted therapies. Group 5: treatment of the underlying condition, with supportive medicines when required.
Instantly Connect with our Specialists
Hospitals for Pulmonary Hypertension in Malaysia
Parkway Pantai
Kuala Lumpur, Malaysia
Parkway Pantai located in Kuala Lumpur, Malaysia is accredited by JCI. Also listed below are some of the most prominent infrastructural details:
- Capacity of 335 beds
- 200+ specialist Doctors
- Critical Care Unit
- Neonatal Intensive Care Unit
- Operating Theatre
- International Patient Care Center
- Types of rooms available- Premier Suite, Supreme Suite, Deluxe Single Room, 2-bedded room, 4-bedded room, Deluxe Suite, Premier Single room, and Supreme Single room
Prince Court Medical Centre
Kuala Lumpur, Malaysia
Prince Court is a private medical facility in the center of Kuala Lumpur that has 277 individual beds. Our dedication is to provide you with the best treatment possible from the time you arrive until you depart, healthier and happier. We are well-known for our top-notch facilities, cutting-edge technology, and friendly customer service.
Ara Damansara Medical Centre
Kuala Lumpur, Malaysia
Situated at the junction of Petaling Jaya and Shah Alam, close to the Oasis Ara, Ara Damansara Medical Centre boasts a serene, luxurious ambiance.
The Centre has been awarded several prestigious awards such as the Global Health Asia Pacific Awards 2023, Newsweek Best Specialized Hospital APAC 2023, Healthcare Asia Awards 2023, and Malaysian Healthcare Wellness Excellence.
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose Malaysia for Pulmonary Hypertension Treatment?
- Multidisciplinary PH Care: Specialised centres may involve cardiologists, pulmonologists, pulmonary vascular specialists, cardiothoracic surgeons, radiologists, and rehabilitation professionals.
- Advanced Diagnostics: Major centres may provide echocardiography, right-heart catheterisation, cardiac MRI, CT imaging, V/Q scanning, pulmonary function testing, and haemodynamic assessment.
- Targeted Medical Therapy: Eligible patients may access medicines that target different pathways involved in pulmonary arterial hypertension.
- CTEPH Treatment: Selected centres may provide pulmonary endarterectomy, balloon pulmonary angioplasty, and medical management for chronic thromboembolic pulmonary hypertension.
- Advanced Cardiac and Respiratory Care: Patients with complex disease may receive coordinated management of right-heart failure, arrhythmias, chronic lung disease, and other associated conditions.
- Specialised Rehabilitation: Pulmonary and cardiac rehabilitation programmes may help selected patients improve exercise capacity and functional independence.
- Advanced Disease Management: Patients with severe disease may be evaluated for advanced therapies and transplantation when clinically appropriate.
- International Patient Support: Many major Malaysian hospitals provide help with medical records, appointments, treatment coordination, accommodation, interpretation (where available), and follow-up arrangements.
Frequently Asked Questions
Reviewer
Dr. Nityanand Tripathi
Interventional Cardiologist
29 Years of Experience
With a rich experience of more than 29 years, Dr. Nityanand has gained a vast spectrum of skills and expertise in performing all types of complex cardiac procedures. He is an expert in clinical & interventional cardiology and electrophysiology. He studied his medicine (MBBS) and MD from the Institute of Medical Sciences of Banaras Hindu University, Varanasi, and later completed his DM in Cardiology from the prestigious King George Medical University, Lucknow. View More
Last Reviewed - January 2026